July 23, 2014

The Food and Drug Administration on Wednesday announced approval for Zydelig (idelalisib) to treat patients with chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic lymphoma.

April 23, 2014

Specialty pharmacy operator Diplomat has access to dispense Arzerra, a cancer treatment with a recently expanded indication, the company noted Tuesday.

April 21, 2014

GlaxoSmithKline and Genmab A/S announced last week that the Food and Drug Administration has approved a supplemental biologic license application for the use of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia for whom fludarabine-based therapy is considered inappropriate.

September 8, 2010

NEW YORK British drug maker GlaxoSmithKline and biotech company Genmab have started a late-stage trial...

June 30, 2010

British drug maker GlaxoSmithKline has inked a co-development and commercialization agreement with Genmab, the drug...

February 18, 2010

The Food and Drug Administration has approved a drug made by Roche subsidiary Genentech and...